Janney Montgomery Scott
ALXN

Janney Montgomery Scott’s Alexion Pharmaceuticals ALXN Stock Holding History

Janney Montgomery Scott’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-38,451
Closed -$6.01M – 2424
2020
Q4 		$6.01M Sell
38,451
-6,655
-15% -$855K 0.03% 483
2020
Q3 		$5.16M Buy
45,106
+1,277
+3% +$138K 0.03% 475
2020
Q2 		$4.92M Sell
43,829
-392
-0.9% -$41.6K 0.03% 460
2020
Q1 		$3.97M Buy
44,221
+10,637
+32% +$1.04M 0.03% 457
2019
Q4 		$3.63M Sell
33,584
-545
-2% -$58.3K 0.02% 572
2019
Q3 		$3.34M Buy
34,129
+11,408
+50% +$1.29M 0.02% 569
2019
Q2 		$2.98M Buy
22,721
+2,627
+13% +$339K 0.02% 584
2019
Q1 		$2.72M Buy
20,094
+1,339
+7% +$166K 0.02% 594
2018
Q4 		$1.83M Buy
18,755
+1,707
+10% +$202K 0.02% 673
2018
Q3 		$2.37M Sell
17,048
-173
-1% -$21.7K 0.02% 645
2018
Q2 		$2.14M Sell
17,221
-265
-2% -$31K 0.02% 658
2018
Q1 		$1.95M Buy
17,486
+4,069
+30% +$486K 0.02% 661
2017
Q4 		$1.6M Buy
13,417
+34
+0.3% +$4.14K 0.02% 738
2017
Q3 		$1.88M Sell
13,383
-158
-1% -$21.5K 0.02% 641
2017
Q2 		$1.65M Buy
13,541
+5,186
+62% +$604K 0.02% 647
2017
Q1 		$1.01M Buy
8,355
+671
+9% +$86.5K 0.01% 832
2016
Q4 		$940K Sell
7,684
-834
-10% -$102K 0.01% 796
2016
Q3 		$1.04M Buy
+8,518
New +$1.1M 0.02% 642
2016
Q2 		– Sell
-6,790
Closed -$945K – 1242
2016
Q1 		$945K Sell
6,790
-537
-7% -$78.8K 0.02% 536
2015
Q4 		$1.4M Sell
7,327
-242
-3% -$42.3K 0.04% 443
2015
Q3 		$1.18M Buy
7,569
+1,211
+19% +$221K 0.03% 475
2015
Q2 		$1.15M Buy
6,358
+1,322
+26% +$228K 0.02% 713
2015
Q1 		$873K Buy
5,036
+618
+14% +$112K 0.02% 972
2014
Q4 		$817K Buy
4,418
+333
+8% +$61.7K 0.02% 970
2014
Q3 		$677K Buy
4,085
+250
+7% +$41.1K 0.01% 1067
2014
Q2 		$599K Sell
3,835
-1,482
-28% -$234K 0.01% 1110
2014
Q1 		$809K Buy
5,317
+513
+11% +$81.6K 0.02% 844
2013
Q4 		$638K Sell
4,804
-312
-6% -$37.4K 0.02% 933
2013
Q3 		$594K Buy
+5,116
New +$561K 0.02% 900

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janney Montgomery Scott's ALXN Position: Q1 2021 in Review

Janney Montgomery Scott sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 38,451 shares — an estimated $6.01M sold.

Janney Montgomery Scott first reported a position in ALXN in Q3 2013 and held it in 29 quarters. The position peaked at $6.01M in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Janney Montgomery Scott reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Janney Montgomery Scott sold 38,451 Alexion Pharmaceuticals shares in Q1 2021, an estimated $6.01M.
  • Janney Montgomery Scott first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 29 quarters.
  • Janney Montgomery Scott's Alexion Pharmaceuticals position peaked at $6.01M in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Janney Montgomery Scott's 13F filing for Q1 2021, filed 27 Apr 2021.